World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
63
Citations
14240
World Ranking
3027
National Ranking
1420

D. Gray Heppner publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where D. Gray Heppner sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 114 publications — 5th percentile

5% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

D. Gray Heppner D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where D. Gray Heppner sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 63 D-Index — 40th percentile

40% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

D. Gray Heppner is affiliated with Crozet BioPharma in the United States and has contributed to research primarily within the field of Medicine. Their work spans multiple subfields including Infectious Diseases, Public Health, Environmental and Occupational Health, Molecular Biology, and Immunology.

The scientist's research focuses heavily on SARS-CoV-2 and COVID-19, with an emphasis on clinical research studies related to COVID-19 as well as vaccine development and immunoinformatics approaches. Additionally, Heppner has been involved in studies related to Malaria Research and Control, mosquito-borne diseases, and the complement system in diseases.

Recent publications include:

  • A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2 (2022), published in Emerging Microbes & Infections
  • A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naïve adults (2024), published in Vaccine

Frequent collaborators in research include:

  • Shixia Wang
  • Chang Yi Wang
  • Hui-Kai Kuo
  • Wen-Jiun Peng
  • Juin-Hua Huang

Heppner's work has appeared predominantly in the journals Emerging Microbes & Infections and Vaccine, reflecting their focus on infectious disease and immunological research within clinical and public health contexts.

Best Publications

  • A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.

    J A Stoute;M Slaoui;D G Heppner;P Momin

  • Protection of Humans against Malaria by Immunization with Radiation-Attenuated Plasmodium falciparum Sporozoites

    Stephen L. Hoffman;Lucy M. L. Goh;Thomas C. Luke;Imogene Schneider

  • Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.

    Samuel J McConkey;William H H Reece;Vasee S Moorthy;Daniel Webster

  • Randomized, Double-Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria-Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection

    Kent E. Kester;James F. Cummings;Opokua Ofori-Anyinam;Christian F. Ockenhouse

  • A field trial to assess a blood-Stage malaria vaccine

    Mahamadou A. Thera;Ogobara K. Doumbo;Drissa Coulibaly;Matthew B. Laurens

  • Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.

    D. M. Gordon;T. W. McGovern;U. Krzych;J. C. Cohen

  • Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya.

    Bernhards R. Ogutu;Odika J. Apollo;Denise McKinney;Willis Okoth

  • Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria

    Kent E. Kester;Denise A. McKinney;Nadia Tornieporth;Christian F. Ockenhouse

  • Malaria Blood Stage Parasites Activate Human Plasmacytoid Dendritic Cells and Murine Dendritic Cells through a Toll-Like Receptor 9-Dependent Pathway

    Sathit Pichyangkul;Kosol Yongvanitchit;Utaiwan Kum-arb;Hiroaki Hemmi

  • Protective Immunity Induced with Malaria Vaccine, RTS,S, Is Linked to Plasmodium falciparum Circumsporozoite Protein-Specific CD4+ and CD8+ T Cells Producing IFN-γ

    Peifang Sun;Robert Schwenk;Katherine White;Jose A. Stoute

  • Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.

    D. Gray Heppner;Kent E. Kester;Christian F. Ockenhouse;Nadia Tornieporth

  • Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand

    F Nosten;C Luxemburger;D E Kyle;W R Ballou

  • Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A

    Michele D. Spring;James F. Cummings;Christian F. Ockenhouse;Sheetij Dutta

  • Update on the clinical development of candidate malaria vaccines

    W. Ripley Ballou;Myriam Arevalo-Herrera;Daniel Carucci;Thomas L. Richie

  • Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design

    Kelley M. VanBuskirk;Matthew T. O'Neill;Patricia De La Vega;Alexander G. Maier

  • Salmonella typhi Vaccine Strain CVD 908 Expressing the Circumsporozoite Protein of Plasmodium falciparum: Strain Construction and Safety and Immunogenicity in Humans

    C. Gonzalez;D. Hone;F. R. Noriega;C. O. Tacket

  • Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children.

    Suharyono;C Simanjuntak;H Totosudirjo;N Witham

  • Common and Divergent Immune Response Signaling Pathways Discovered in Peripheral Blood Mononuclear Cell Gene Expression Patterns in Presymptomatic and Clinically Apparent Malaria

    Christian F. Ockenhouse;Wan Chung Hu;Kent E. Kester;James F. Cummings

  • First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers.

    Michele Spring;Jittawadee Murphy;Robin Nielsen;Megan Dowler

  • Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial.

    Mahamadou A. Thera;Ogobara K. Doumbo;Drissa Coulibaly;Dapa A. Diallo

Frequent Co-Authors

Joe Cohen
Joe Cohen GlaxoSmithKline (United Kingdom)
Kent E. Kester
Kent E. Kester Walter Reed Army Institute of Research
W. Ripley Ballou
W. Ripley Ballou International AIDS Vaccine Initiative
David E. Lanar
David E. Lanar Walter Reed Army Institute of Research
Christian F. Ockenhouse
Christian F. Ockenhouse Walter Reed Army Institute of Research
Urszula Krzych
Urszula Krzych United States Army Research Laboratory
Christopher V. Plowe
Christopher V. Plowe University of Maryland, Baltimore
Amanda J. Leach
Amanda J. Leach Charles Darwin University
Ogobara K. Doumbo
Ogobara K. Doumbo University of Bamako
Arthur M. Krieg
Arthur M. Krieg University of Massachusetts Chan Medical School

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology opens doors to diverse healthcare careers, many of which can be further enhanced through specialized nursing programs. For example, professionals interested in mental health may consider exploring the cheapest online pmhnp programs. These affordable programs help students gain credentials in psychiatric-mental health nursing, complementing immunology knowledge with strong patient care skills.

Nurses aiming to elevate their careers should evaluate salary prospects, especially when advancing their qualifications. The dnp salary varies by location but generally reflects the high demand for nurse practitioners with doctoral degrees, reinforcing the value of further education.

For those already working as Family Nurse Practitioners (FNPs), transitioning into acute care nursing can be a strategic move. Guidance on obtaining acute care certification for fnp is crucial for successfully advancing into roles that require acute patient management, often related to immunological conditions.

Accelerated paths like accelerated fnp programs provide a faster route to becoming a nurse practitioner. These programs offer intensive, practical training that aligns well with the evolving demands in healthcare connected to immunology and patient care.

Best Scientists Citing D. Gray Heppner

Trending Scientists

Recently Published Articles